Skip to main content

Table 2 The comparisons of complement component in the pMN, FSGS, MCD patients and healthy controls

From: Complement activation products in the circulation and urine of primary membranous nephropathy

 

Value, median (IQR)

Abnormal, n (%)

Value, median (IQR)

Abnormal, n (%)

Value, median (IQR)

Abnormal, n (%)

Value, median (IQR)

Cut-off value

 

pMN (n = 134)

FSGS (n = 72)

MCD (n = 18)

Healthy Controls (n = 40)

P-C1q

0.8 (0.5–1.1)

24 (17.9)

0.9 (0.6–1.8) **

25 (36.8) **

0.6 (0.4–0.7) *

1 (3.6)

0.6 (0.5–0.9)

1.2

P-C4d

0.2 (0.1–0.3)

134 (100)

0.2 (0.1–0.3)

67 (98.5)

0.01 (0.00–0.01) **

0 (0) **

0.02 (0.01–0.02) **

0.03

P-MBL

19.5 (6.8–35.9)

24 (17.9)

1.1 (0.5–2.7) **

0 (0) **

23.9 (8.7–37.9)

5 (17.9)

16.3 (6.8–23.8)

41.8

P-Bb

0.008 (0.005–0.01)

28 (20.9)

0.01 (0.00–0.02)

17 (25.0)

0.005 (0.004–0.008) **

3 (10.7)

0.006 (0.004–0.008) **

0.01

P-Properdin

0.2 (0.1–0.3)

2 (1.5)

–

–

0.2 (0.1–0.3)

0 (0)

0.2 (0.1–0.3)

0.5

P-C3a

85.8 (11.8–120.0)

128 (95.5)

6.4 (3.2–20.8) **

54 (79.4) **

1.7 (1.0–3.3) **

7 (25.0) **

0.9 (0.4–1.5) **

2.5

P-C5a

2.4 (0.3–23.8)

100 (74.6)

0.1 (0.1–0.3) **

14 (20.6) **

0.05 (0.02–0.11) **

0 (0) **

0.6 (0.03–0.11) **

0.3

P-MAC

2.4 (1.4–3.8)

8 (6.0)

4.9 (2.8–10.3) **

28 (41.2) **

1.7 (1.2–2.3) **

0 (0)

2.5 (1.5–3.3)

5.6

 

pMN (n = 106)

FSGS (n = 55)

MCD (n = 18)

Healthy Controls (n = 40)

U-C1q

0.0 (0.0–0.2)

6 (5.7)

0.3 (0.1–0.7) **

2 (3.6)

0.0 (0.0–0.3)

2 (11.1)

1.1 (0.0–2.8) **

5.9

U-C4d

0.1 (0.0–1.2)

37 (34.9)

–

–

13.0 (5.5–25.0) **

17 (94.4) **

0.0 (0.0–0.7) **

0.7

U-MBL

0.0 (0.0–0.0)

10 (9.4)

0.8 (0.0–5.7) **

47 (85.5) **

0.0 (0.0–0.0)

0 (0)

0.0 (0.0–0.0)

0.0

U-Bb

1.0 (0.4–1.9)

2 (1.9)

0.01 (0.01–0.10) **

0 (0)

10.5 (5.6–28.2) **

8 (44.4) **

4.5 (1.5–4.6) **

10.8

U-Properdin

0.0 (0.0–13.7)

16 (15.1)

–

–

654.3 (213.9–1775.7) **

18 (100) **

0.0 (0.0–0.0) *

28.9

U-C3a

21.5 (10.8–46.5)

53 (50)

1257.9 (118.3–12,195.0) **

48 (87.3) **

0.0 (0.0–14.7) **

4 (22.2) *

3.7 (1.6–5.8) **

22.2

U-C5a

7.9 (0.7–33.6)

40 (37.7)

4398.6 (173.4–29,984.6) **

53 (96.4) **

51.1 (9.2–137.1) *

13 (72.2) *

3.3 (1.5–6.5) *

13.3

U-MAC

1.0 (0.3–2.6)

31 (29.2)

5.4 (0.8–24.7) **

36 (65.5) **

0.0 (0.0–2.14) *

4 (22.2)

0.0 (0.0–0.01) **

2.5

  1. P plasma, U urine. *: P < 0.05; **: P < 0.001; compared to pMN patients. Data was shown as median (inter-quartile range). Cut-off value was defined as mean + 2 SD. The level of plasma complement was corrected by eGFR (corrected level = measured level/eGFR) and the unit was and (μg/ml)/(ml/min/1.73m2) for C1q, C4d, Bb, properdin, and (ng/ml)/(ml/min/1.73m2) for C3a, C5a, MAC, MBL. The level of urinary complement was corrected by urinary creatinine and urinary protein (corrected level = measured level / (urinary creatinine × urinary protein)) and the unit was ng/mg/g for C1q, MBL, Bb, MAC, and pg/mg/g for C3a, C5a, pg/mg/g properdin, and μg/mg/g for C4d
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us